Resilient Eckert & Ziegler stock holds steady as Berenberg reiterates Buy rating
Published on 08/27/2026 at 13:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Eckert & Ziegler SE (ISIN DE0005659700) stock is trading in the low-teens euro range in late August 2026 as investors weigh a reiterated Buy rating and an unchanged target against a modest pullback from the 52-week high, with the shares most recently quoted at EUR 13.13 on August 26, 2026 and showing a negative move over the past five trading days per a detailed market overview in the corporate news report.
Analyst stance and recent price performance
The latest note cited in that corporate news overview shows that a major German bank has reaffirmed its Buy stance on Eckert & Ziegler and kept its price target at EUR 23, providing a clear valuation marker against the current market price in the analyst rating summary. With the shares last changing hands at EUR 13.13 on August 26, 2026, this implies an upside of EUR 9.87 per share to the stated target, a gap of more than 75 percent that underscores how cautiously the market is currently valuing the company relative to that benchmark according to the corporate news data. Over the last five trading days, Eckert & Ziegler stock has recorded a move of -2.46 percent, signaling mild short-term weakness rather than a sharp selloff, and that same report places the shares within a 52-week trading corridor from EUR 12.97 to EUR 18.77.
The Vienna Stock Exchange statistics for August 27, 2026 give another snapshot of trading conditions, listing Eckert & Ziegler SE under ISIN DE0005659700 with a last price of EUR 13.15, an intraday change of -1.65 percent, a total volume of 200 shares, total value of EUR 2,630, and a market capitalization of EUR 835,232,770 in the global market segment in the Vienna Stock Exchange statistics. That quote is slightly above the EUR 13.13 level reported for August 26, 2026, indicating that despite the daily percentage decline on the Vienna venue, the stock is still trading very close to the lower bound of its stated 52-week range, a positioning that may be relevant for value-focused investors who watch support levels near prior lows.
Operational backdrop and year-target confirmation
Beyond the price action, the operational backdrop in 2026 includes the company’s recovery from a cyberattack earlier in the year and issues affecting the delivery of gallium generators. A fresh article in a German market news feed on August 27, 2026 highlights that Eckert & Ziegler has largely resolved the operational disruptions stemming from the cyberattack in February and the temporary delivery stop for gallium generators, and crucially that management is confirming the full-year objectives for 2026 despite those headwinds in the guidance-related news item. The confirmation of year targets, even after a notable operational incident, suggests that the company expects to meet its earlier revenue and earnings guidance, reinforcing the broader narrative of resilience that is reflected in the current analyst stance.
Although detailed mid-year revenue and profit figures for Eckert & Ziegler’s latest reporting period are not spelled out in the day-filtered snippets at hand, the emphasis on having caught up with production and shipments after the February issues implies that the first half of 2026 did not see a fundamental derailment of the business plan according to the same operational update. In context, the combination of a still-confirmed annual guidance and a Buy rating with a target at EUR 23 points to a situation where the market is factoring in cautious expectations, but key external and internal signals are aligned in anticipating stable or improving fundamentals over the remainder of 2026.
Valuation gap and investor takeaways
The valuation gap between the current trading band and the reiterated EUR 23 target is one of the most striking numerical signals for Eckert & Ziegler stock in late August 2026. Taking the EUR 13.13 price from August 26, 2026 as a reference, the discount to the target is more than three quarters of the target value, meaning the stock trades at less than 60 percent of the level suggested by that valuation benchmark as the corporate news comparison shows. For investors, this kind of gap often raises questions about whether the market expects slower growth, higher risk, or a normalization of margins that is not yet fully reflected in formal guidance.
At the same time, the 52-week range from EUR 12.97 to EUR 18.77 and the current positioning close to the lower end of that corridor indicate that the shares have already come down materially from the highs reached earlier within the year per the same price-range overview. The five-day performance of -2.46 percent is modest in absolute terms, but when viewed against the broader drift from the upper half of the range toward the lower bound it signals a phase of consolidation or fatigue rather than a decisive rally. For retail investors who look at both technical levels and fundamental guidance, the combination of a resilient guidance message and a discounted price level can be a prompt to examine detailed earnings and segment data once the next full report is published.
Radiation technology and gallium generators as a core product
Eckert & Ziegler SE is known for its specialized radiation technology products, and the 2026 news flow specifically refers to gallium generators whose deliveries were temporarily halted following the February cyberattack in the product-related update. Gallium generators are used in nuclear medicine to produce gallium-based isotopes for diagnostic imaging, serving hospitals and radiopharmacies that rely on precise, reliable sources of radioisotopes. This product category is strategically important because it sits at the intersection of medical technology, regulatory oversight, and long-term contracts with healthcare providers.
The fact that Eckert & Ziegler has largely caught up with the delivery backlog for these generators by August 27, 2026 supports the view that the company’s core operational capabilities in nuclear medicine technology remain intact despite the earlier disruption. For patients and clinics, stable supply of such generators means that diagnostic procedures using gallium isotopes can continue without significant interruption, and for the company it means that revenue streams tied to consumable and hardware deliveries in this segment can normalize in the second half of the year according to the same operational note. In the broader market narrative, a specialized product like gallium generators also anchors Eckert & Ziegler’s positioning as a niche provider in the nuclear-medical equipment space, differentiating it from more diversified industrial groups.
Shares and latest quote context
Eckert & Ziegler stock is traded in the euro area, and the most recent composite view from late August 2026 places the price in a tight band around EUR 13.13 to EUR 13.15, with the Vienna Stock Exchange listing a last price of EUR 13.15 on August 27, 2026, an intraday percentage change of -1.65 percent, and a market capitalization of EUR 835,232,770 for Eckert & Ziegler SE in the global market segment in the Vienna market statistics. The earlier corporate news piece reports a price of EUR 13.13 as of August 26, 2026, timestamped at 12:29 p.m. ET for cross-market comparison, and places the 52-week trading range between EUR 12.97 and EUR 18.77 for the shares in the same corporate report. Together, these figures give retail investors a concise picture of where the stock stands relative to both its own history and a prominent analyst valuation benchmark as of August 27, 2026.
Go deeper
More on Eckert & Ziegler stock
Investor Relations
Company: Eckert & Ziegler SE
ISIN: DE0005659700
Ticker: EUZ
Exchange: Vienna Stock Exchange, global market
Price (as of August 27, 2026, 1:16 p.m. ET): EUR 13.15
Market cap: EUR 835.23 million (as of August 27, 2026)
Sector / Industry: Health care equipment and nuclear medicine technology
Index membership: Not specified
